Safety and immunogenicity of bovine rotavirus vaccine RIT 4237 in 3-month-old infants

Y. Maldonado, L. Hestvik, M. Wilson, T. Townsend, J. O'Hare, S. Wee, Robert H Yolken

Research output: Contribution to journalArticle

Abstract

To assess the safety and immunogenicity of bovine rotavirus vaccine, we administered attenuated strain RIT 4237 to 54 inner-city infants randomized to one of three groups in a double-blind fashion to receive a dose at 3 and 5 months of age of either placebo, vaccine virus at 107 TCID50/ml, or vaccine virus at 108 TCID50/ml. Vaccination began in early fall 1984, and continued through spring 1985. Forty-nine infants received one dose of vaccine or placebo; 43 received both doses of vaccine or placebo. At 2 and 3 months after vaccination, homologous geometric mean neutralizing antibody titers were significantly higher in children who received either dose of vaccine compared with placebo recipients. Cumulative seroconversion to bovine rotavirus after either dose of vaccine virus was 87% at 6 months of age. Seroconversion was significantly higher (P

Original languageEnglish (US)
Pages (from-to)931-935
Number of pages5
JournalJournal of Pediatrics
Volume109
Issue number6
DOIs
StatePublished - 1986

Fingerprint

Rotavirus Vaccines
Vaccines
Safety
Placebos
Viruses
Vaccination
Rotavirus
Neutralizing Antibodies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Safety and immunogenicity of bovine rotavirus vaccine RIT 4237 in 3-month-old infants. / Maldonado, Y.; Hestvik, L.; Wilson, M.; Townsend, T.; O'Hare, J.; Wee, S.; Yolken, Robert H.

In: Journal of Pediatrics, Vol. 109, No. 6, 1986, p. 931-935.

Research output: Contribution to journalArticle

Maldonado, Y, Hestvik, L, Wilson, M, Townsend, T, O'Hare, J, Wee, S & Yolken, RH 1986, 'Safety and immunogenicity of bovine rotavirus vaccine RIT 4237 in 3-month-old infants', Journal of Pediatrics, vol. 109, no. 6, pp. 931-935. https://doi.org/10.1016/S0022-3476(86)80271-2
Maldonado, Y. ; Hestvik, L. ; Wilson, M. ; Townsend, T. ; O'Hare, J. ; Wee, S. ; Yolken, Robert H. / Safety and immunogenicity of bovine rotavirus vaccine RIT 4237 in 3-month-old infants. In: Journal of Pediatrics. 1986 ; Vol. 109, No. 6. pp. 931-935.
@article{ee110ff92bfd4194b4f89c2169857b12,
title = "Safety and immunogenicity of bovine rotavirus vaccine RIT 4237 in 3-month-old infants",
abstract = "To assess the safety and immunogenicity of bovine rotavirus vaccine, we administered attenuated strain RIT 4237 to 54 inner-city infants randomized to one of three groups in a double-blind fashion to receive a dose at 3 and 5 months of age of either placebo, vaccine virus at 107 TCID50/ml, or vaccine virus at 108 TCID50/ml. Vaccination began in early fall 1984, and continued through spring 1985. Forty-nine infants received one dose of vaccine or placebo; 43 received both doses of vaccine or placebo. At 2 and 3 months after vaccination, homologous geometric mean neutralizing antibody titers were significantly higher in children who received either dose of vaccine compared with placebo recipients. Cumulative seroconversion to bovine rotavirus after either dose of vaccine virus was 87{\%} at 6 months of age. Seroconversion was significantly higher (P",
author = "Y. Maldonado and L. Hestvik and M. Wilson and T. Townsend and J. O'Hare and S. Wee and Yolken, {Robert H}",
year = "1986",
doi = "10.1016/S0022-3476(86)80271-2",
language = "English (US)",
volume = "109",
pages = "931--935",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Safety and immunogenicity of bovine rotavirus vaccine RIT 4237 in 3-month-old infants

AU - Maldonado, Y.

AU - Hestvik, L.

AU - Wilson, M.

AU - Townsend, T.

AU - O'Hare, J.

AU - Wee, S.

AU - Yolken, Robert H

PY - 1986

Y1 - 1986

N2 - To assess the safety and immunogenicity of bovine rotavirus vaccine, we administered attenuated strain RIT 4237 to 54 inner-city infants randomized to one of three groups in a double-blind fashion to receive a dose at 3 and 5 months of age of either placebo, vaccine virus at 107 TCID50/ml, or vaccine virus at 108 TCID50/ml. Vaccination began in early fall 1984, and continued through spring 1985. Forty-nine infants received one dose of vaccine or placebo; 43 received both doses of vaccine or placebo. At 2 and 3 months after vaccination, homologous geometric mean neutralizing antibody titers were significantly higher in children who received either dose of vaccine compared with placebo recipients. Cumulative seroconversion to bovine rotavirus after either dose of vaccine virus was 87% at 6 months of age. Seroconversion was significantly higher (P

AB - To assess the safety and immunogenicity of bovine rotavirus vaccine, we administered attenuated strain RIT 4237 to 54 inner-city infants randomized to one of three groups in a double-blind fashion to receive a dose at 3 and 5 months of age of either placebo, vaccine virus at 107 TCID50/ml, or vaccine virus at 108 TCID50/ml. Vaccination began in early fall 1984, and continued through spring 1985. Forty-nine infants received one dose of vaccine or placebo; 43 received both doses of vaccine or placebo. At 2 and 3 months after vaccination, homologous geometric mean neutralizing antibody titers were significantly higher in children who received either dose of vaccine compared with placebo recipients. Cumulative seroconversion to bovine rotavirus after either dose of vaccine virus was 87% at 6 months of age. Seroconversion was significantly higher (P

UR - http://www.scopus.com/inward/record.url?scp=0023003420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023003420&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(86)80271-2

DO - 10.1016/S0022-3476(86)80271-2

M3 - Article

VL - 109

SP - 931

EP - 935

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 6

ER -